A detailed history of Private Wealth Partners, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Private Wealth Partners, LLC holds 2,425 shares of VRTX stock, worth $963,379. This represents 0.09% of its overall portfolio holdings.

Number of Shares
2,425
Previous 1,500 61.67%
Holding current value
$963,379
Previous $703,000 60.31%
% of portfolio
0.09%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$460.0 - $505.78 $425,500 - $467,846
925 Added 61.67%
2,425 $1.13 Million
Q1 2024

May 08, 2024

SELL
$407.69 - $446.08 $770,534 - $843,091
-1,890 Reduced 55.75%
1,500 $627,000
Q3 2023

Nov 06, 2023

SELL
$338.18 - $362.46 $16,909 - $18,123
-50 Reduced 1.45%
3,390 $1.18 Million
Q2 2023

Aug 03, 2023

SELL
$314.42 - $351.91 $28,297 - $31,671
-90 Reduced 2.55%
3,440 $1.21 Million
Q1 2023

May 03, 2023

BUY
$283.23 - $323.1 $999,801 - $1.14 Million
3,530 New
3,530 $1.11 Million
Q3 2021

Nov 12, 2021

SELL
$181.39 - $202.99 $2.6 Million - $2.91 Million
-14,355 Closed
0 $0
Q2 2021

Aug 12, 2021

SELL
$187.49 - $221.1 $85,870 - $101,263
-458 Reduced 3.09%
14,355 $2.89 Million
Q1 2021

May 04, 2021

BUY
$207.02 - $241.31 $193,356 - $225,383
934 Added 6.73%
14,813 $3.18 Million
Q4 2020

Feb 03, 2021

BUY
$207.01 - $276.09 $509,037 - $678,905
2,459 Added 21.53%
13,879 $3.28 Million
Q3 2020

Oct 29, 2020

BUY
$255.65 - $303.1 $198,384 - $235,205
776 Added 7.29%
11,420 $3.11 Million
Q2 2020

Jul 31, 2020

BUY
$225.48 - $295.8 $91,319 - $119,799
405 Added 3.96%
10,644 $3.09 Million
Q1 2020

Apr 24, 2020

BUY
$199.77 - $247.81 $2.05 Million - $2.54 Million
10,239 New
10,239 $2.44 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $102B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Private Wealth Partners, LLC Portfolio

Follow Private Wealth Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Wealth Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Wealth Partners, LLC with notifications on news.